

REMARKS


The specification has been amended to incorporate the paragraph regarding cross-reference to related applications and statement regarding federally funded research.

The claims have been amended as shown above. In particular, claim 1 has been amended to be drawn to the zinc finger protein as described on page 72, lines 10-20 that modulates expression of a *chk2* gene. Claims 2, 8, 9 and 10 have been amended to specify that the gene is a *chk2* gene and claims 3, 7 and 8 have been amended to remove multiple dependencies.

Entry of the foregoing amendments is requested prior to substantive examination of pending claims 1-10.

Respectfully submitted,

Date: March 20, 2006

By: 
Dahna S. Pasternak
Registration No. 41,411
Attorney for Applicants

ROBINS & PASTERNAK LLP
1731 Embarcadero Road
Suite 230
Palo Alto, CA 94306
Tel. (650) 493-3400
Fax. (650) 493-3440